Antihypertensive activity and molecular interactions of irbesartan in complex with 2‐hydroxypropyl‐β‐cyclodextrin. (21st July 2020)
- Record Type:
- Journal Article
- Title:
- Antihypertensive activity and molecular interactions of irbesartan in complex with 2‐hydroxypropyl‐β‐cyclodextrin. (21st July 2020)
- Main Title:
- Antihypertensive activity and molecular interactions of irbesartan in complex with 2‐hydroxypropyl‐β‐cyclodextrin
- Authors:
- Leonis, Georgios
Christodoulou, Eirini
Ntountaniotis, Dimitrios
Chatziathanasiadou, Maria V.
Mavromoustakos, Thomas
Naziris, Nikolaos
Chountoulesi, Maria
Demetzos, Costas
Valsami, Georgia
Damalas, Dimitrios E.
Tzakos, Andreas G.
Thomaidis, Nikolaos S.
Karageorgos, Vlasios
Liapakis, Georgios - Abstract:
- Abstract: Irbesartan (IRB) exerts beneficial effects either alone or in combination with other drugs on numerous diseases, such as cancer, diabetes, and hypertension. However, due to its high lipophilicity, IRB does not possess the optimum pharmacological efficiency. To circumvent this problem, a drug delivery system with 2‐hydroxypropyl‐β‐cyclodextrin (2‐HP‐β‐CD) was explored. The 1:1 complex between IRB and 2‐HP‐β‐CD was identified through ESI QTF HRMS. Dissolution studies showed a higher dissolution rate of the lyophilized IRB–2‐HP‐β‐CD complex than the tablet containing IRB at pH = 1.2. DSC results revealed the differences of the thermal properties between the complex and various mixtures consisting of the two components, namely IRB and 2‐HP‐β‐CD. Interestingly, depending on the way the mixture preparation was conducted, different association between the two components was observed. Molecular dynamics (MD) simulations predicted the favorable formation of the above complex and identified the dominant interactions between IRB and 2‐HP‐β‐CD. In vitro pharmacological results verified that the inclusion complex not only preserves the binding affinity of IRB for AT1R receptor, but also it slightly increases it. As the complex formulation lacks the problems of the tablet, our approach is a promising new way to improve the efficiency of IRB. Abstract : An inclusion complex of antihypertensive drug irbesartan with 2‐hydroxylpropyl‐β‐cyclodextrin was prepared and characterizedAbstract: Irbesartan (IRB) exerts beneficial effects either alone or in combination with other drugs on numerous diseases, such as cancer, diabetes, and hypertension. However, due to its high lipophilicity, IRB does not possess the optimum pharmacological efficiency. To circumvent this problem, a drug delivery system with 2‐hydroxypropyl‐β‐cyclodextrin (2‐HP‐β‐CD) was explored. The 1:1 complex between IRB and 2‐HP‐β‐CD was identified through ESI QTF HRMS. Dissolution studies showed a higher dissolution rate of the lyophilized IRB–2‐HP‐β‐CD complex than the tablet containing IRB at pH = 1.2. DSC results revealed the differences of the thermal properties between the complex and various mixtures consisting of the two components, namely IRB and 2‐HP‐β‐CD. Interestingly, depending on the way the mixture preparation was conducted, different association between the two components was observed. Molecular dynamics (MD) simulations predicted the favorable formation of the above complex and identified the dominant interactions between IRB and 2‐HP‐β‐CD. In vitro pharmacological results verified that the inclusion complex not only preserves the binding affinity of IRB for AT1R receptor, but also it slightly increases it. As the complex formulation lacks the problems of the tablet, our approach is a promising new way to improve the efficiency of IRB. Abstract : An inclusion complex of antihypertensive drug irbesartan with 2‐hydroxylpropyl‐β‐cyclodextrin was prepared and characterized with a variety of biophysical and computational approaches. It was shown that the complex formulation as a drug delivery device significantly improved irbesartan's pharmacologic efficiency by enhancing its aqueous solubility. … (more)
- Is Part Of:
- Chemical biology & drug design. Volume 96:Number 1(2020)
- Journal:
- Chemical biology & drug design
- Issue:
- Volume 96:Number 1(2020)
- Issue Display:
- Volume 96, Issue 1 (2020)
- Year:
- 2020
- Volume:
- 96
- Issue:
- 1
- Issue Sort Value:
- 2020-0096-0001-0000
- Page Start:
- 668
- Page End:
- 683
- Publication Date:
- 2020-07-21
- Subjects:
- 2‐hydroxypropyl‐β‐cyclodextrin -- binding assays -- differential scanning calorimetry -- hypertension -- irbesartan -- mass spectrometry -- molecular dynamics
Drugs -- Design -- Periodicals
Pharmaceutical chemistry -- Periodicals
Biochemistry -- Periodicals
615.19005 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&NEWS=n&PAGE=toc&D=ovft&AN=01253034-000000000-00000 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1747-0285 ↗
http://www.blackwell-synergy.com/loi/jpp ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cbdd.13664 ↗
- Languages:
- English
- ISSNs:
- 1747-0277
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3139.120000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 13550.xml